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ABSTRACT
Bivalirudin is a direct thrombin inhibitor used
during percutaneous coronary intervention
(PCI). Treatment with bivalirudin compared to
heparin plus glycoprotein IIb/IIIa inhibitors
(GPI) reduced bleeding complications, but
resulted in higher rates of ischemic events,
including acute stent thrombosis in ST
segment elevation myocardial infarction
(STEMI) patients. Thus, it may be considered a
reasonable alternative antithrombotic agent in
patients at high risk of bleeding undergoing
PCI. However its superiority over heparin alone
is questioned particularly in the era of novel
antiplatelet agents and transradial PCI.
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INTRODUCTION
Thrombosis is the main pathophysiologic
mechanism of acute coronary syndromes
(ACS) and thrombin plays a pivotal role in the
coagulation cascade and thrombus formation in
this clinical setting [1]. Bivalirudin is a direct
thrombin inhibitor that provides potent and
effective control of thrombin activity and has
been proved a useful and effective therapeutic
agent in a broad spectrum of patients with
coronary syndromes undergoing percutaneous
coronary intervention (PCI) [2, 3].
Bivalirudin is an oligopeptide analogue of the
naturally produced hirudin that binds reversibly
to both the active site and exosite I of thrombin
[4]. Bivalirudin, contrary to heparin, inhibits
effectively both the free fibrin-bound thrombin,
is not inactivated by platelet factor 4, does not
require antithrombin for its activity, does not
bind to proteins and matrices other than
thrombin, has low immunogenic potential, and
does not cause heparin-induced
thrombocytopenia [4, 5]. Despite these
theoretical advantages of bivalirudin, in clinical
practice its superiority over heparin is doubted.
Our review aims to collect and interpret all
relevant data regarding bivalirudin’s efficacy in
PCI and clarify if it could be considered as a
reasonable antithrombotic option in different
clinical settings during PCI.
This article is based on previously conducted
studies and does not involve any new studies of
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human or animal subjects performed by any of
the authors.
BIVALIRUDIN IN PCI
Bivalirudin and Low to Moderate Risk
Patients Undergoing PCI
Unfractionated heparin (UFH) has been the
main antithrombotic therapy during PCI. The
additional administration of glycoprotein IIb/
IIIa inhibitors (GPI) during PCI is helpful to
prevent thrombotic complications in patients
with ACS, but not in low risk patients pretreated
with thienopyridines [6]. Therapy with GPI is
not used universally because, as potent platelet
inhibitors, they carry an increased bleeding risk.
Bivalirudin, a direct thrombin inhibitor with
predictable biophysical availability, is an
alternative antithrombotic agent which can be
used instead of heparin.
The establishment of bivalirudin as an
antithrombotic agent was based primarily on
the results of BAT (Bivalirudin Angioplasty
Trial). Patients with unstable or postinfarction
angina were randomly assigned to receive either
bivalirudin or heparin immediately before
angioplasty. Bivalirudin therapy compared
with heparin was associated with a 22%
reduction of ischemic and 62% reduction of
bleeding complications, respectively [7]. The
exclusive use of balloon-only angioplasty,
without stent implantation, the absence of
pretreatment with thienopyridines, the high
dose of heparin administration (bolus dose of
175 units/kg and infusion at a rate of 15 units/
kg for 18–24 h), and the outdated regimen of
bivalirudin (bolus dose of 1 mg/kg and infusion
at a rate of 2.5 mg/kg/h for 4 h and 0.2 mg/kg/h
for 14–20 h) make the results of this study
difficult to compare to current interventional
practice. The feasibility of bivalirudin during
PCI in the contemporary era of elective
coronary stenting and dual antiplatelet
therapy was evaluated by CACHET
(Comparison of Abciximab Complications
with Hirulog for Ischemic Events Trial) and
REPLACE-1 (Randomized Evaluation of PCI
Linking Angiomax to Reduced Clinical
Events-1) trials. Bivalirudin with provisional or
planned GPI compared to heparin plus GPI
resulted in lower rates of major bleeding and
similar rates of ischemic events according to the
CACHET [8] trial. In the REPLACE-1 trial the
ischemic and hemorrhagic end points were
approximately 20% lower among patients
randomized to bivalirudin compared to those
randomized to heparin. However, the beneficial
effects of bivalirudin on bleeding were observed
only in the subgroup of patients who did not
receive GPI [9]. These observations were in part
the rationale for use of provisional rather than
planned GPI in the bivalirudin arm of the
following REPLACE-2 trial.
The REPLACE-2 (Randomized Evaluation of
PCI Linking Angiomax to Reduced Clinical
Events-2) trial compared bivalirudin with the
combination of heparin plus GPI. Patients with
positive stress test, unstable and stable angina
were enrolled in this trial. Patients were
randomized to receive either bivalirudin with
provisional GPI or heparin plus planned GPI
(abciximab or eptifibatide). The composite
primary end point occurred in 9.2% of
patients participating in the bivalirudin group
and 10% of patients who received heparin and
GPI (p = 0.32) (Table 1). Regarding the ischemic
events, bivalirudin with provisional GPI was
proved not inferior to GPI plus heparin, despite
the not statistically significant trend toward a
higher incidence of non-Q wave MI observed in
the bivalirudin group. A remarkable result of
REPLACE-2 was the 41% relative reduction of
major in-hospital bleeding in the bivalirudin
arm (2.4% vs. 4.1%, p\0.001) [10] which
resulted in a trend of better survival rates after
6 months and 1-year follow-up [11].
ISAR–REACT 3 (Intracoronary Stenting and
Antithrombotic Regimen: Rapid Early Action
for Coronary Treatment 3), a double-blind trial,
was designed to evaluate bivalirudin as
monotherapy, exclusively in patients with
stable or unstable angina undergoing PCI and
compared it with UFH alone. For that reason
GPI were administered in only 0.2% of patients
in each group. Concerning the quadruple
primary end point, bivalirudin did not provide
any net clinical benefit, or any harm, compared
with heparin at 30-day follow-up (Table 1). The
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Table 1 Summary of key clinical trials examining the role of bivalirudin in coronary artery diseases
Year Trial Population Primary end point Result
2003 REPLACE-2 Patients without
acute MI
Composite of death, MI, urgent repeat
revascularization within 30 days of
randomization or in-hospital major
bleeding
9.2% bivalirudin vs. 10%
heparin plus GPI,
p = 0.32
2006 ACUITY ACS patients 1st: 30-day composite ischemic end point
(death, MI, unplanned revascularization
for ischemia)
2nd: 30-day major bleeding
3rd: 30-day net clinical outcome
(composite of ischemia or major
bleeding)
(a) 7.7% bivalirudin plus
GPI vs. 7.3% heparin plus
GPI, p = 0.39
(b) 7.8% bivalirudin alone
vs. 7.3% heparin plus GPI,
p = 0.3
(a) 5.3% bivalirudin plus
GPI vs. 5.7% heparin plus
GPI, p = 0.38
(b) 3.0% bivalirudin alone
vs. 5.7% heparin plus GPI,
p\0.001
(a) 11.8% bivalirudin plus
GPI vs. 11.7% heparin plus
GPI, p = 0.93
(b) 10.1% for bivalirudin
alone vs. 11.7% for heparin
plus GPI, p = 0.02
2008 HORIZONS-AMI STEMI patients 1st: 30-day major bleeding
2nd: 30-day combined adverse clinical
events (death, reinfarction, target vessel
revascularization for ischemia, stroke, and
major bleeding)
4.9% bivalirudin vs. 8.3%
heparin plus GPI,
p\0.001
9.2% for bivalirudin vs.
12.1% for heparin plus
GPI, p = 0.005
2008 ISAR-REACT 3 Stable or
unstable angina
Composite of death, MI, urgent target
vessel revascularization for ischemia
within 30 days for randomization or
major bleeding during hospitalization
8.3% bivalirudin vs. 8.7%
heparin, p = 0.57
2011 ISAR-REACT 4 NSTEMI
patients
Composite end point of death, large
recurrent MI, urgent target vessel
revascularization or major bleeding
within 30 days from randomization
11% bivalirudin vs. 10.9%
abciximab plus heparin,
p = 0.94
2013 EUROMAX STEMI patients
transferred for
PPCI
Composite of death or major bleeding at
30 days




beneficial effects of bivalirudin on major
bleeding rate were verified in this trial. On the
other hand a trend toward a higher incidence of
MI in the bivalirudin arm has blunted any
clinical benefit resulting from the lower risk of
bleeding [12]. At 1 year neither the composite
end point of death, MI, and target vessel
revascularization nor its individual
components separately differed in the trial’s
troponin-negative patients, independently of
the antithrombotic regimen they received.
Furthermore the stent thrombosis events were
identical for both bivalirudin and heparin
treatment groups [13].
The role of bivalirudin in patients
undergoing elective PCI was further
investigated by smaller trials. The ARNO
(Antithrombotic Regiments and Outcome)
trial, a double randomized trial, compared
bivalirudin and heparin plus protamine in
both troponin-positive and negative-patients
undergoing PCI. Although heparin was
neutralized by protamine at the end of
intervention, in-hospital major bleeding rate
was fourfold less in the bivalirudin arm,
supporting that bivalirudin’s safe profile
regarding the bleeding risk is not only due to
its short half time. Also bivalirudin
unexpectedly reduced the ischemic events,
despite the more frequent use of abciximab in
the heparin group. The 30-day secondary
efficacy end point of death, MI, and
unplanned revascularization was greater in the
heparin arm; this is a unique observation that
has not been previously reported. With regard
to the fewer thrombotic complications and the
lower rates of major bleeding, bivalirudin was
associated with better 1- and 6-month net
clinical outcome [14].
The bivalirudin’s beneficial effects on
bleeding were questioned by the NAPLES III
trial (Novel Approaches in Preventing or
Limiting Event III). Bivalirudin compared to
heparin failed to reduce in-hospital bleeding in
high risk bleeding patients undergoing elective
PCI through the femoral approach. The reduced
Table 1 continued
Year Trial Population Primary end point Result
2014 HEAT-PPCI STEMI patients Composite of all-cause mortality,
cerebrovascular accident, reinfarction or
unplanned target lesion revascularization
at 28 days
8.7% for bivalirudin vs. 5.7%
for heparin, p = 0.01




In-hospital major bleeding 3.3% bivalirudin vs. 2.6%
UFH, p = 0.54
2014 BRIGHT MI patients A composite of death from any cause,
reinfarction, ischemia-driven target vessel
revascularization, stroke, or any bleeding
at 30 days
8.8% bivalirudin vs. 13.2%
heparin, vs. 17% for
heparin plus tiroﬁban,
p\0.001
2015 MATRIX STEMI and
NSTEMI
patients
Whether bivalirudin with bailout GP IIb/
IIIa inhibitor (GPI) use was superior to




heparin, p = 0.43
NSTEMI patients: 15.9%
bivalirudin vs. 16.4%
heparin, p = 0.74
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heparin dose used in this trial and the absence
of concomitant GPI administration in the UFH
arm may explain the similar rates of bleeding
between the two groups. Regarding ischemic
events including MI, stent thrombosis, and
revascularization at 30 days and 1 year, no
differences emerged between the two
antithrombotic strategies. The trial result is
interesting and raises doubt on the positive
impact of bivalirudin on bleeding and thus may
influence clinical practice [15].
The different and sometimes controversial
results of the cited studies can be difficult to
explain, compare, and interpret because of the
different patient populations and treatment
algorithms. In current European guidelines for
revascularization, in stable coronary disease
patients undergoing PCI, bivalirudin has a
Class I recommendation with level of evidence
C in case of heparin-induced thrombopenia and
Class IIa recommendation with level of
evidence A in high bleeding risk patients
undergoing PCI [16].
Bivalirudin and High Risk Patients
Undergoing PCI
Bivalirudin has also been evaluated in patients
with ACS. The PROTECT-TIMI 30 trial
randomized ACS patients undergoing PCI and
examined whether eptifibatide plus UFH or
enoxaparin had better coronary flow reserve
after PCI compared to bivalirudin. Although
bivalirudin monotherapy was associated with
higher coronary flow reserve, treatment with
eptifibatide resulted in improved myocardial
perfusion and decreased duration of ischemia
after PCI. Minor but not major bleeding and
transfusion rates were lower among patients
treated with bivalirudin, supporting again its
beneficial effects regarding bleeding [17]. The
ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trial was the first
large-scale, prospective, randomized trial
comparing bivalirudin monotherapy with
provisional use of GPI, bivalirudin plus GPI,
and heparin (either UFH or enoxaparin) plus
GPI in the clinical setting of ACS. Patients with
either myocardial infarction without persistent
ST segment elevation (NSTEMI) or
unstable angina were enrolled in this trial. The
basic finding of this trial was that bivalirudin
monotherapy with the provisional use of GPI
compared with heparin plus GPI reduced
significantly the rate of major bleeding,
without a simultaneous increase in the
ischemic events even among the highest risk
patients enrolled, thus resulting in a reduction
of the net clinical outcome (Table 1).
Bivalirudin monotherapy also decreased the
incidence of bleeding from any cause, minor
bleeding according to TIMI scale, and blood
transfusions. Interestingly there was an increase
of the ischemic events in the subgroup of
patients who participated in the bivalirudin
monotherapy group and did not receive a
thienopyridine before angioplasty, compared
with patients treated with heparin plus GPI. In
contrast, pretreatment with a thienopyridine
resulted in similar incidence of ischemic events
in both groups. Therefore the administration of
thienopyridines before angioplasty is desirable
in order to optimize the outcomes of
bivalirudin as a monotherapy, an approach
that is consistent with current guidelines [18].
The comparison of bivalirudin plus GPI and
heparin plus GPI did not reveal a winner. Both
antithrombotic therapies resulted in similar
30-day rates of the composite ischemia end
point, major bleeding, and the net clinical
outcome end point [2].
Patients with ACS with non-persistent ST
segment elevation represent a higher risk
patient group [19]. The ISAR-REACT 4
(Intracoronary Stenting and Atithrombotic
Regimen: Rapid Early Action for Coronary
Treatment 4) trial was a randomized trial
evaluating non-inferiority of bivalirudin versus
heparin plus abciximab in NSTEMI patients
who needed an early invasive
revascularization. The antithrombotic
approach with the combination of abciximab
plus heparin, compared to bivalirudin, failed to
reduce the rate of primary end point (Table 1).
Conversely, it increased the risk of bleeding
without providing any benefit in protection
against ischemic events. Therefore, bivalirudin
was associated with a lower incidence of major
and minor bleeding and showed an
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anti-ischemic protection similar to that offered
by abciximab and heparin without any
increased risk of stent thrombosis or death
[20]. The beneficial effects of bivalirudin on
bleeding did not translate to a better 1-year
survival. Nevertheless, bivalirudin was not
inferior to heparin plus abciximab and
provided comparable long-term clinical
outcomes including death, MI, and target
vessel revascularization [20, 21].
Bivalirudin was also evaluated in patients
with NSTEMI receiving fondaparinux. SWITCH
III is a randomized, multicenter study which
aimed to evaluate the safety of bivalirudin
versus UFH in patients with NSTEMI, initially
treated with fondaparinux and urgent PCI. The
investigators did not reveal any significant
differences in hemorrhagic or ischemic end
points between the two groups. Bivalirudin
was not inferior to UFH regarding bleeding,
death, MI, acute revascularization, stent
thrombosis, and reinfarction [22].
Furthermore, an observational retrospective
analysis showed that treatment with
bivalirudin plus provisional GPI during
elective or urgent PCI in patients who initially
received fondaparinux resulted in statistically
lower rates of clinically apparent bleeding or
bleeding requiring transfusions and a trend to a
lower mortality compared with UFH plus
provisional GPI [23]. In the current European
Society of Cardiology (ESC) guidelines for
NSTEMI, the use of bivalirudin in ACS patients
pretreated with fondaparinux is not clarified
because, at the time of publication, the only
anticoagulant evaluated with fondaparinux
during PCI was UFH [18].
Is Bivalirudin Monotherapy Superior
to Heparin Alone in the Treatment
of NSTEMI Patients Undergoing PCI?
Previously a Swedish group extracted and
analyzed retrospective data from the Swedish
Coronary Angiography and Angioplasty
Registry (SCAAR) and compared the 30-day
mortality between treatment with bivalirudin
alone and heparin (UFH or LMWH) in patients
with NSTEMI who underwent PCI. Of note,
contrary to the previously mentioned studies,
patients who received GPI were excluded. A
total of 41,534 consecutive patients who were
treated with either heparin alone or bivalirudin
between 2005 and 2011 were included in this
study [24]. The results were quite impressive
and unexpected. Treatment with heparin was
associated with a significant decrease in 30-day
mortality compared to bivalirudin, a finding
that should be verified by a randomized trial.
The current ESC guidelines for NSTEMI gave a
class I, level of evidence A, recommendation for
bivalirudin (0.75 mg/kg iv bolus followed by
1.75 mg/kg/h for up to 4 h after the procedure)
as an alternative to UFH plus GPI receptor
inhibitors [18].
Bivalirudin and Patients with ST Segment
Elevation Myocardial Infarction
Undergoing PCI
Patients with STEMI represent a population
requiring prompt reperfusion with primary PCI
(PPCI) being the best option [25]. The
HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stents in Acute
Myocardial Infarction) study was the first
prospective, randomized multicenter trial that
aimed to compare bivalirudin to heparin plus a
GPI (abciximab or eptifibatide) in STEMI
patients who were treated with PPCI.
Approximately 7.2% of patients assigned to
bivalirudin received GPI because of either no
reflow or high thrombus burden after PPCI [3].
As primary end points were defined, the
combined clinical events were determined as
the combination of major bleeding and major
adverse cardiovascular events (MACE; death,
reinfarction, target vessel revascularization for
ischemia, and stroke) and major bleeding not
related to coronary artery bypass graft (CABG)
at 30 days. Patients who were assigned to
bivalirudin had a significant reduction of net
adverse clinical events (9.2% vs. 12.1%,
p = 0.005) compared to heparin plus GPI
(Table 1) mainly owing to the lower rates of
major bleeding (4.9% vs. 8.3%; p\0.001).
Importantly, both rates of 30-day mortality
from cardiac causes and all-cause mortality
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were significantly lower in the bivalirudin arm
(1.8% vs. 2.9%, p = 0.03 and 2.1% vs. 3.1%,
p = 0.047, respectively). Rates of reinfarction,
target vessel revascularization, and stroke did
not differ significantly between the two
anticoagulant options. Bivalirudin treatment
resulted in lower rates of blood transfusions
and thrombocytopenia. However there was a
significant 1.0% increase of stent thrombosis
during the first 24 h after PCI among patients
treated with bivalirudin [3].
The superiority of bivalirudin over the
combination of heparin and GPI was
substantially confirmed after 1-year follow-up.
Noteworthy, the differences in survival between
the two groups were widened between 30 days
and 1 year, indicating that the beneficial effects
of bivalirudin do not only relate to the
periprocedural period but also translates to
long-term positive impact on mortality.
Additionally, at the end of the 1-year
follow-up, the rates of stent thrombosis were
similar between the two anticoagulation
treatments, indicating that the initial increase
of stent thrombosis in the bivalirudin group was
counterbalanced by a subsequent decrease of
stent thrombosis between 24 h and 1 year,
compared to the control group [26]. After a
3-year follow-up, treatment with bivalirudin
was independently associated with a 43%
reduction in 3-year cardiac mortality, even
after a multivariate analysis taking into
account major bleeding, thrombocytopenia,
and reinfarction [27].
Although HORIZONS-AMI remains the
largest study that established the utility of
bivalirudin in STEMI patients undergoing
PPCI, a careful reading of its design reveals an
important limitation [28]. More than 65% of
the patients assigned to the bivalirudin group
had received a bolus of UFH before
randomization. Therefore the bivalirudin was
not actually compared as a monotherapy to
heparin plus GPI. Patients treated with
bivalirudin who received UFH before
randomization had a more favorable prognosis
compared to those who did not (4.6% vs. 7.2%
for the primary end point of the study). This
fact raised same questions about the beneficial
effects of UFH in patients treated with
bivalirudin during PPCI. A study from Sweden
aimed to evaluate retrospectively the effect of
the addition of bolus UFH in administration to
bivalirudin in patients with STEMI undergoing
PPCI. Bivalirudin monotherapy during PCI was
compared with periprocedural bivalirudin plus
UFH. The main finding was that the additional
administration of bolus UFH in STEMI patients
receiving bivalirudin during PCI resulted in
lower rates of death or definite target lesion
thrombosis. A probable interpretation is that
bivalirudin alone cannot provide effective
anticoagulation in this high thrombotic
clinical setting, because of its short half time.
Considering that the pretreatment with UFH
has been proved not to increase bleeding risk in
STEMI patients receiving bivalirudin, an extra
bolus administration of UFH in this group of
patients should be reasonable [29].
Many changes occurred since the
HORIZONS-AMI trial was conducted. Novel
P2Y12 inhibitors, such as ticagrelor and
prasugrel, and the radial artery access have
increasingly been adopted. The EUROMAX
(European Ambulance Acute Syndrome
Angiography) trial was an international,
randomized trial that aimed to assess whether
bivalirudin administered during patient’s
transport for PPCI was superior to heparin plus
optional GPI in the contemporary era of radial
artery access and new antiplatelet agents.
Among patients assigned to the bivalirudin
group, only a small proportion received either
heparin (2.2%) or GPI (11.5%). On the other
hand, most of the patients (69.1%) participating
in the heparin group had received GPI. The
trial’s primary end point occurred in 5.1% of the
patients received bivalirudin and 8.5% of the
patients treated with heparin plus optional use
of GPI (p = 0.001) (Table 1). Prehospital
administration of bivalirudin was associated
with reduction of both major and minor
bleeding as well as transfusions, compared
with the heparin group, regardless of the
choice of arterial access and P2Y12 inhibitors.
Despite the HORIZONS-AMI trial, the beneficial
effects of bivalirudin on bleeding were not
translated to a decrease in mortality. The risk
of acute stent thrombosis within 24 h was
greater in the bivalirudin group compared
Cardiol Ther
with the control group. The prolonged,
reduced-dose infusion of bivalirudin and the
use of new P2Y12 with more rapid and potent
action failed to reduce this risk. The increased
rates of stent thrombosis resulted in a
non-significant increased incidence of
reinfarction and ischemia-driven
revascularization in the bivalirudin group. In
conclusion, the EUROMAX trial suggested
bivalirudin as an anticoagulant treatment in
STEMI patients, with lower rates of bleeding,
but higher rates of acute stent thrombosis [30].
Is Bivalirudin Monotherapy Superior
to Heparin Alone in the Treatment
of STEMI Patients Undergoing PCI?
The single-center HEAT-PPCI (How Effective are
Antithrombotic Therapies in Primary
Percutaneous Coronary Intervention) trial
compared bivalirudin and heparin in patients
stented for STEMI. The HEAT-PPCI trial revealed
heparin as the clear winner, as patients treated
with heparin were less likely to have either
reinfarction or stent thrombosis compared to
those in the bivalirudin arm, without a
concomitant increase of bleeding events
(Table 1). This was the first trial that
demonstrated bivalirudin’s inferiority
compared to heparin [31]. However the
BRIGHT (Bivalirudin Monotherapy vs. Heparin
Monotherapy vs. Heparin Plus Tirofiban AMI
Patients Undergoing Coronary Intervention)
trial, a randomized multicenter trial, showed
that bivalirudin in NSTEMI and STEMI patients
resulted in lower rates of the combined primary
end point of death, reinfarction,
ischemia-driven vessel revascularization,
stroke, or bleeding at 30 days (Table 1) and
1 year compared to either UFH alone or UFH
plus tirofiban. Bleeding events were
significantly reduced by the bivalirudin
strategy compared to heparin without any
concomitant increase in ischemic events,
including stent thrombosis. Possibly the
higher dose in the heparin monotherapy arm
(100 U/kg, greater than was used in HEAT-PPCI)
may explain the increased bleeding events in
the heparin monotherapy group. Also the
prolonged high dose (1.75 mg/kg/h)
bivalirudin infusion lasting 3–4 h after PCI
potentially could relate to the lack of stent
thrombosis in the bivalirudin arm [32]. The
MATRIX Antithrombin study, part of the
MATRIX program was a randomized
comparison of bivalirudin with UFH in acute
coronary syndrome patients with or without ST
segment elevation. GPI use was restricted in
angiographic complications in the bivalirudin
arm and it was left to the discretion of the
investigator in the UFH arm. The MACE end
point, a composite end point that included
death, MI, or stroke, was not statistically
different between the two treatment regimens
independently of the presence or not of ST
segment elevation. However, bivalirudin
compared to heparin was associated with
lower rates of all-cause and cardiovascular
mortality at 30 days both in patients with
(0.68, 95% CI 0.46–1.01, p = 0.053 and 0.67,
95% CI 0.45–1.00, p = 0.048) and without (0.77,
95% CI 0.41–1.46, p = 0.43 and 0.76, 95% CI
0.40–1.47, p = 0.42) ST segment elevation. The
rates of stent thrombosis and myocardial
infarction at 30 days were similar between the
two groups in patients with and without ST
segment elevation. Regarding the net clinical
event end point—a composite end point that
included death, MI, stroke, and major
bleeding—there was no significant difference
between the two antithrombin regimens.
However, bleeding rates were significantly
reduced with bivalirudin. Bivalirudin
treatment resulted in lower rates of BARC
(Bleeding Academic Research Consortium) 3
and 5 both in STEMI patients (0.60, 95% CI
0.39–0.92; p = 0.019) and in patients without ST
segment elevation (0.47, 0.26–0.85; p = 0.011)
[33].
The results of the trials that compared
bivalirudin and heparin monotherapies are
controversial. Thus, a meta-analysis aimed to
clarify the superiority or not of bivalirudin
compared to heparin, in the broad spectrum of
patients undergoing PCI. Pooling and analyzing
data from all relevant randomized trials, this
study showed that treatment with bivalirudin
resulted in increased rates of MACE, mainly due
to the increased incidence of MI and
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ischemia-driven revascularization. On the other
hand bivalirudin reduced the risk of bleeding
events. However the magnitude of this
reduction was influenced by the concomitant
use of GPI. The greater benefit regarding
bleeding achieved with the bivalirudin strategy
was seen when GPI use was provisional in the
bivalirudin arm but predominantly planned in
the heparin arm. When GPI was used on a
provisional basis in both anticoagulant
regiments the reduction of bleeding still did
not significantly favor bivalirudin.
Furthermore, bivalirudin was associated with
an increased risk of stent thrombosis and
specifically acute stent thrombosis in STEMI
patients. The use of the third-generation P2Y12
inhibitors in HEAT-PPCI and EUROMAX trials
failed to limit this risk [34]. A second
meta-analysis systematically evaluated the
ischemic and bleeding efficacy of the various
anticoagulant therapies recommended in
STEMI in order to establish the optimal
antithrombotic strategy. Bivalirudin was
associated with a 48% and 32% decrease in
major bleeding when compared to UFH plus
GPI and heparin, respectively. On the other
hand, bivalirudin resulted in a 65% increase in
stent thrombosis, 39% increase in MI, and a
44% increase in urgent revascularization, when
compared with UFH with or without GPI [35].
Three recent meta-analyses, while confirming
the increased incidence of acute stent
thrombosis with bivalirudin, show no
difference in the rate of MACE between
bivalirudin and heparin with or without GPI
[36–38]. However, a meta-analysis that
compared the extended (up to 3 h) high dose
(1.75/kg/h) of bivalirudin used in the BRIGHT
trial and in a subgroup of patients in MATRIX
and EUROMAX trials to heparin with or
without GPI revealed no significant differences
in acute stent thrombosis rates between the two
antithrombotic options in STEMI patients.
Furthermore this study, analyzing data from
six large-scale randomized trials, confirmed that
bivalirudin with or without prolonged infusion
compared to conventional antithrombotic
treatment in the STEMI setting resulted in
significantly lower rates of major bleeding and
all-cause mortality at 30 days [39]. In a rapidly
evolving radial access world, another
meta-analysis evaluated the interaction
between bivalirudin and radial approach in
ACS patients undergoing PCI. Bivalirudin’s
superiority regarding major bleeding is
restricted only to patients with femoral access
but not those undergoing PCI using the radial
approach. On the other hand, the radial
compared to femoral access resulted in
significantly lower major bleeding rates only
in patients treated with heparin, independently
of the use of GPI. Thus, the combined use of
radial approach and bivalirudin does not offer
any additional benefit regarding bleeding as
opposed to the use of either one alone [40].
The ESC guidelines for the STEMI
management, based mainly on the results of
the HORIZONS-AMI trial, recommend (class I
recommendation and level of evidence B)
therapy with bivalirudin and bailout use of
GPI over UFH plus GPI, in all patients
undergoing PCI independently of whether
they are at high risk of bleeding or not [25].
However, taking into account the current
European revascularization guidelines [16] and
the results of recently published studies [31], we
believe that heparin should be the preferred
antithrombotic choice in this clinical setting.
Bivalirudin results in higher rates of acute stent
thrombosis [30, 31, 34] and should be
considered as an alternative strategy only in
patients at high risk of bleeding. Further
investigation with more randomized trials is
needed to investigate whether higher doses of
bivalirudin with pronged infusion rates could
prevent acute stent thrombosis.
The VALIDATE-SWEDEHEART trial, a
multicenter randomized trial, will compare
head-to-head bivalirudin and heparin alone in
STEMI and NSTEMI patients pretreated with the
new potent P2Y12 inhibitors and is expected to
reveal the best antithrombotic approach in the
era of new antiplatelet agents [41].
CONCLUSION
The introduction of bivalirudin in the
management of patients undergoing PCI was
welcomed by interventional cardiologists
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because, compared to heparin plus GPI, it was
associated with better clinical outcomes, mainly
driven by the lower rates of bleeding. However,
data on the superiority of bivalirudin compared
to heparin alone suggest that bivalirudin, an
expensive direct thrombin inhibitor, does not
offer any clinical advantage over heparin, a
cheaper but effective anticoagulant agent, in
the era of radial PCI and novel antiplatelet
drugs.
Impact on Daily Practice
In line with current European guidelines for
revascularization, our review doubts the
superiority of bivalirudin over heparin in
patients undergoing PCI and should be used
only in patients at high risk of bleeding. UFH
should be the first-choice anticoagulant during
PPCI, as bivalirudin increases acute stent
thrombosis rates.
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